Literature DB >> 1495499

Influenza basic polymerase 2 peptides are recognized by influenza nucleoprotein-specific cytotoxic T lymphocytes.

R W Anderson1, J R Bennink, J W Yewdell, W L Maloy, J E Coligan.   

Abstract

Cytotoxic T lymphocytes (CTL) play an important role in limiting viral infections and in eradicating virus from host tissues. Recent progress in understanding the processing and presentation of viral antigens to CTL indicates that the CTL antigen receptor recognizes peptides derived from viral proteins that are bound to an antigen binding groove present in class I major histocompatibility complex (MHC) molecules. In understanding CTL anti-viral responses and in creating vaccines designed to elicit CTL responses, it is critical to identify the portions of viral proteins that bind class I molecules and are recognized by T cell receptors. Previous findings have indicated that a significant portion of the CTL response of H-2d mice to influenza virus is specific for one of the viral polymerases (PB2). To identify the region of PB2 naturally processed and presented by influenza virus-infected mouse cells to CTL, 31 PB2 peptides of 9-16 residues in length were chosen and chemically synthesized. Two peptides, PB2, residues 146-159 and 187-195, were found to sensitize histocompatible target cells for recognition by influenza virus-specific CTL. When CTL were generated to individual viral proteins using influenza-vaccinia recombinant viruses, we found, to our surprise, that PB2-specific CTL failed to recognize cells sensitized with PB2 peptides 146-159 and 187-195. Further analysis showed that these PB2 peptides were, in fact, recognized by nucleoprotein (NP)-specific CTL generated by NP-vac virus priming and influenza A virus stimulation, or NP peptide stimulation in vitro of NP-vac or influenza A-primed CTL. These results demonstrate that while screening peptide libraries one cannot assume that positive peptides necessarily identify the viral protein to which the CTL response is directed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1495499     DOI: 10.1016/0161-5890(92)90041-u

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  14 in total

Review 1.  Heterologous immunity between viruses.

Authors:  Raymond M Welsh; Jenny W Che; Michael A Brehm; Liisa K Selin
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells.

Authors:  H Wedemeyer; E Mizukoshi; A R Davis; J R Bennink; B Rehermann
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses.

Authors:  L K Selin; S R Nahill; R M Welsh
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

4.  Cytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1 clades.

Authors:  A Bertoletti; F Cham; S McAdam; T Rostron; S Rowland-Jones; S Sabally; T Corrah; K Ariyoshi; H Whittle
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

5.  Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections.

Authors:  L K Selin; K Vergilis; R M Welsh; S R Nahill
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

6.  Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells.

Authors:  A B Kulkarni; H C Morse; J R Bennink; J W Yewdell; B R Murphy
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

7.  Characterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization.

Authors:  Sara Venturini; Donald E Mosier; Dennis R Burton; Pascal Poignard
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  Quantitating T cell cross-reactivity for unrelated peptide antigens.

Authors:  Jeffrey Ishizuka; Kristie Grebe; Eugene Shenderov; Bjoern Peters; Qiongyu Chen; Yanchun Peng; Lili Wang; Tao Dong; Valerie Pasquetto; Carla Oseroff; John Sidney; Heather Hickman; Vincenzo Cerundolo; Alessandro Sette; Jack R Bennink; Andrew McMichael; Jonathan W Yewdell
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

9.  Presentation by a major histocompatibility complex class I molecule of nucleoprotein peptide expressed in two different genes of an influenza virus transfectant.

Authors:  H Isobe; T Moran; S Li; A Young; S Nathenson; P Palese; C Bona
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

10.  Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations.

Authors:  L K Selin; S M Varga; I C Wong; R M Welsh
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.